Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated ...
Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...
And thanks for Stifel for having us here this afternoon. So yes, if I look at 2026 as we exited the prior year, we're entering this year, with a great deal of enterprise-wide momentum, and this comes ...
ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...
Functional connectivity reveals brain attractors that match predictions of free‑energy‑minimizing attractor theory, yielding an interpretable generative model of brain dynamics in rest, task, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results